Discussing Mindset Pharma’s 2022 Milestones and Future Plans with James Lanthier
Mindset's recent accomplishments have set the stage for its psychedelic drug candidates to be first in human clinical trials by 2023.
Similar Posts
Dr. Matthew Johnson: Psychedelics, Consciousness, DMT Experiences & The CIA
In this much anticipated Psychedelic Spotlight podcast, we get to…
DEA Quadruples Psilocybin Manufacturing for Research in Final 2021 Production Quotas
Drug Enforcement Agency also hugely boosts MDMA and DMT quotas “in response to the nationwide public interest in hallucinogenic controlled substances research.”
Psychedelic Business Spotlight: October 22
This week in psychedelic business news: UK fast tracks DMT for major depressive disorder; Field Trip Health expands its clinical presence in the US; and another psychedelic pharmaceuticals company prepares for the Nasdaq.
Interview With Dimensions Health Centers
In today’s episode of the Psychedelic Spotlight podcast, we spotlight Dimensions Health Centers who are creating a new paradigm for hospitality by helping people to improve and transform their lives by drawing on the restorative power of nature, spa rituals, delicious food, and psilocybin-inspired ceremonies in safe, legal and luxurious settings.
Lower Doses of Psilocybin May Still Have Antidepressant Effects
Psilocybin taken at low doses could have powerful antidepressant effects, according to new research findings.
Suing the City of Oakland for Mushroom Raid with Dave Hodges
In this episode, Dave speaks to Dennis Walker about how Oakland PD raided his church and confiscated $200,000 worth of sacraments.